Nav: Home

Monash research provides insights into why older people respond poorly to cancer treatment

June 19, 2018

It's called the Silver Tsunami - the increased incidence of cancer with ageing, combined with the rapidly ageing population means that the Australian health system needs to prepare for an onslaught of cancer diagnoses.

A new study out of Monash University, published today in the journal Cell Reports, may have found a group of immune cells that increase in number with age but are too worn out to fight off diseases.

Professor Nicole La Gruta and Dr Kylie Quinn, from Monash University's Biomedicine Discovery Institute, have found that a subset of immune cells, called virtual memory T cells, make up around 5% of T cells in young animal models and humans but accumulate significantly with old age and lose the ability to become activated. Importantly, the Monash researchers found that another subset, called true naïve T cells, retain their capacity to mount an immune response but decline in frequency dramatically with increasing age, from 90 per cent to 30 per cent in animal models and humans. These shifts are likely caused by age-related inflammation or "inflamm-ageing".

According to Professor La Gruta, the accumulation of dysfunctional virtual memory T cells, in addition to the loss of true naïve T cells, may explain why older people have reduced immune responses to cancer and vaccines, and why cancer immunotherapy is less successful in the elderly.

"In cancer immunotherapy, a patient's own T cells are stimulated to kill cancer cells and it has been hugely successful for certain forms of cancer. Unfortunately, older patients or people over 65 years of age respond less well than younger ones," Professor La Gruta said.

"This may be because of the differences we see in these T cell subsets in older versus younger patients," she said.

"Now that we understand the impact of ageing on these T cells, we may be able to selectively target them to improve this cutting edge cancer treatment."

According to Prof La Gruta and Dr Quinn, this may mean developing treatments to remove dysfunctional virtual memory T cells or enrich for functional true naïve T cells during cancer immunotherapy or developing treatments that reduce chronic inflammation to prevent immune decline.

"Using these observations, we may be able to tailor cancer immunotherapy specifically for the needs of an older patient's immune system- this is where medicine must head to meet the needs of our ageing society," Professor La Gruta said.

Cancer - Australian Institute of Health and Welfare

In 2014, people aged 65 and over were estimated to account for more than:
  • half (58 per cent) of new cancer cases diagnosed
  • three-quarters (77 per cent) of cancer related deaths


Overall, for older Australians, lung cancer is the most common cause of death from cancer, followed by prostate, colorectal, pancreatic, and breast cancer (women).

Read the full paper in Cell Reports titled Age-Related Decline in Primary CD8+ T Cell Responses is Associated with the Development of Senescence in Virtual Memory CD8+ T Cells.
-end-
About the Monash Biomedicine Discovery Institute

Committed to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.

Media enquiries:

Tania Ewing
0408 378 422
taniaewing@taniaewing.com

Monash University

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Setbacks
Failure can feel lonely and final. But can we learn from failure, even reframe it, to feel more like a temporary setback? This hour, TED speakers on changing a crushing defeat into a stepping stone. Guests include entrepreneur Leticia Gasca, psychology professor Alison Ledgerwood, astronomer Phil Plait, former professional athlete Charly Haversat, and UPS training manager Jon Bowers.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".